Posted by Michael Wonder on 02 Oct 2023
ICER publishes special report on Eliquis and Xarelto submitted to CMS as part of public comment process on Medicare drug price negotiations
2 October 2023 - Report tailored to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding the information that CMS will use to determine initial offers and pursue price negotiation on selected drugs.
The ICER today posted a Special Report evaluating the evidence on apixaban (Eliquis, Bristol-Myers Squibb) and rivaroxaban (Xarelto, Bayer) for the treatment of non-valvular atrial fibrillation.
